Dr. Ursula Theuretzbacher is founder and principal of the Center for Anti-Infective Agents in Vienna, Austria, since 1988. A microbiologist by training, she dedicated her professional life to antibacterial and antifungal drug R&D as well as appropriate and optimized usage of these drugs. She focuses on resistance and dosing issues from the early development phase to the use of old and new drugs in clinical practice.
She is currently work package leader in the multinational collaborative EU funded project AIDA (Re-developing old antibiotics) and in the multinational public-private partnership project DRIVE-AB (Incentivizing antibacterial drug R&D, funded by the EU Innovative Medicines Initiative=IMI) and partner in the IMI project COMBACTE-MAGNET (Developing new molecules against Gram-Negative Infections). Ursula Theuretzbacher is currently President of the Society of Anti-Infective Pharmacology (ISAP) and Founding President of the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) PK/PD of Anti-Infectives Study Group (EPASG). She is chair of a policy and scientific study group of the International Society of Chemotherapy (ISC), Member of the Executive Committee of the International Society of Infectious Diseases (ISID) and member of the ECCMID Programme Committee
Medical misuse and overuse as well as other market place practices have resulted in widespread resistance to modern antibiotics. Dr. Theureztbacher will talk about the interesting work underway to stimulate and incentivize the research and development of new antibiotics to overcome this critical shortage of effective antibiotics.